menu
    • menu
    [{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clobazam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Aquestive Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive Therapeutics \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clobazam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Assertio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"LGS Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Clobazam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Assertio Therapeutics \/ LGS Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Assertio Therapeutics \/ LGS Foundation"},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Pharmanovia"},{"orgOrder":0,"company":"Cipla","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Clobazam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cipla \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals for Onfi

    Menu

    Onfi

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi

                            Details : Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, N...

                            Brand Name : Frisium

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 18, 2023

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cipla

                            India arrow
                            2024 ACI Convention
                            Not Confirmed

                            Cipla

                            India arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sanofi and Cipla Form Exclusive Distribution Partnership for CNS Portfolio in India

                            Details : Cipla will distribute and promote Sanofi India's CNS product range, including Frisium (clobazam), an anti-epileptic medication, in India.

                            Brand Name : Frisium

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Assertio Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Assertio Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : LGS Foundation

                            Deal Size : $0.1 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation

                            Details : SYMPAZAN (clobazam) is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

                            Brand Name : Sympazan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 17, 2023

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : LGS Foundation

                            Deal Size : $0.1 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Assertio Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Assertio Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent

                            Details : Sympazan® (clobazam), oral film developed with PharmFilm® technology, is a prescription medicine used to treat seizures associated with Lennox-Gastaut Syndrome in people 2 years of age or older. Clobazam positive allosteric modulator of GABA receptor.

                            Brand Name : Sympazan

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aquestive Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Aquestive Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Assertio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

                            Details : Under the terms of the definitive agreement, Aquestive exclusively licensed the product’s intellectual property to Assertio for an upfront payment. Aquestive also entered into a long-term supply agreement with Assertio for Sympazan (clobazam) oral film...

                            Brand Name : Sympazan

                            Molecule Type : Small molecule

                            Upfront Cash : $9.0 million

                            October 27, 2022

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Assertio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth